Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Morton Grove Pharmaceuticals sold to ex-Fujisawa USA President Tambi.

  • News

Executive Summary

MORTON GROVE PHARMACEUTICALS SOLD TO FORMER FUJISAWA USA PRESIDENT TAMBI and Chicago-based William Blair Capital Partners. In a transaction announced Dec. 12, Brian Tambi acquired Morton Grove Pharmaceuticals, Inc. from JVL, Inc., a holding company formed by Jack Van Hulst and William Lyons. Tambi will serve as MGP's chairman, president and CEO. He previously was an exec at Lyphomed when it was acquired by Fujisawa. He was appointed Fujisawa USA president in 1990 and joined Ivax in 1992 as president of its North American pharmaceutical business.

Table

View full table

Tags:
Latest Headlines

US FDA’s Vaccine Office Emerges From Non-COVID-19 Backlog

AstraZeneca’s Farxiga Authorized Generic Aims To Broaden Access As Medicare Price Cut Looms

US FDA Adcomm Reform: Does Listening Session Suggest No Major Near-Term Changes?

It’s Official: FDA Drops Final Rule On LDTs

See All
UsernamePublicRestriction

Register

PS027430

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By